GlassScriptPhysician profile
Jacqueline Helmus
NPI 1902663727
$5,317.06
in general payments reported to CMS, 2019-2025
46 companies · $2,801 in 2025
The $2,801 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,517 · 2025: $2,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,023 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,023.09 |
| Education | $293.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $448.87 | 2024-2025 | Imfinzi, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $377.71 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $368.83 | 2024-2025 | Rybrevant, Darzalex, Tecvayli |
| Novartis Pharmaceuticals Corporation | $329.12 | 2024-2025 | |
| Sobi, INC | $248.19 | 2024-2025 | |
| Gilead Sciences, INC. | $237.25 | 2024-2025 | Trodelvy |
| Pfizer INC. | $236.30 | 2024 | |
| Eisai INC. | $221.13 | 2024-2025 | |
| Celgene Corporation | $187.47 | 2024-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $162.32 | 2024-2025 | Ninlaro, Fruzaqla, Iclusig |
| Exelixis INC. | $161.65 | 2024-2025 | Cabometyx |
| Incyte Corporation | $153.52 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $137.28 | 2024-2025 | Enhertu, Vanflyta, Datroway |
| Glaxosmithkline, LLC. | $125.19 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $120.04 | 2024-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $117.89 | 2024-2025 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $109.73 | 2024-2025 | Onivyde, Somatuline Depot |
| Geron Corporation | $95.90 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $92.33 | 2024 | Cosela, Monoferric |
| Array Biopharma INC | $90.30 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Genentech USA, INC. | $89.96 | 2024-2025 | Perjeta, Phesgo, Kadcyla |
| Regeneron Healthcare Solutions, INC. | $84.57 | 2024-2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $83.71 | 2025 | Ultomiris |
| Iovance Biotherapeutics, INC. | $82.51 | 2025 | Amtagvi |
| Taiho Oncology, INC. | $76.78 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $75.82 | 2025 | Provenge |
| Aveo Pharmaceuticals, INC. | $75.73 | 2024-2025 | |
| Novocure INC. | $68.90 | 2025 | Optune Lua (Novottf-200t) |
| Emd Serono, INC. | $67.70 | 2024-2025 | |
| Beone Medicines USA, INC. | $60.55 | 2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $58.88 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $54.86 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $54.70 | 2024 | Orgovyx |
| Legend Biotech USA INC. | $49.94 | 2025 | Carvykti |
| Lilly USA, LLC | $39.64 | 2024 | Jaypirca, Verzenio |
| Genzyme Corporation | $38.71 | 2025 | |
| Stemline Therapeutics INC. | $36.53 | 2024-2025 | Orserdu |
| Delcath Systems | $34.05 | 2025 | Hepzato Kit |
| Abbvie INC. | $26.34 | 2024 | |
| Tersera Therapeutics LLC | $21.59 | 2024 | Zoladex |
| Deciphera Pharmaceuticals INC. | $21.56 | 2025 | Romvimza, Qinlock |
| Karyopharm Therapeutics INC. | $20.19 | 2024 | Xpovio |
| Adc Therapeutics America, INC. | $19.94 | 2025 | |
| Recordati_rare_diseases_inc. | $18.43 | 2025 | Enjaymo |
| Agios Pharmaceuticals, INC. | $17.28 | 2024 | Pyrukynd |
| Puma Biotechnology, INC. | $17.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Helmus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.